Vanda Pharmaceuticals Inc. has acquired the U.S. and Canadian rights to PONVORY^® (ponesimod), an oral therapy approved for relapsing types of multiple sclerosis (MS), in a new deal with Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company.

Under the terms of the agreement, Vanda paid $100 million to Actelion, the therapy’s original developer.

Ponvory was approved in the U.S. in 2021 for treating adults with relapsing forms of MS. Specifically, it can be used by patients with clinically isolated syndrome, relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS).

It’s also approved in Canada, but only for people with RRMS.

Stifel acted as the exclusive financial advisor to Vanda for this acquisition.